Uso de trastuzumabe para o tratamento de mulheres com câncer de mama HER2 positivo: um estudo farmacoepidemiológico

Uso de trastuzumabe para o tratamento de mulheres com câncer de mama HER2 positivo: um estudo farmacoepidemiológico

Introdução: O câncer de mama é o segundo tipo de câncer mais frequente no mundo, com cerca de 1,67 milhões de casos novos e 521 mil mortes a cada ano. O câncer de mama pode ser classificado em diferentes grupos, sendo o subtipo HER2 positivo um dos mais agressivos e relacionado a um mal prognóst...

Full description

Bibliographic Details
Main Author:	Lorena Rocha Ayres
Other Authors:	Leonardo Régis Leira Pereira
Language:	Portuguese
Published:	Universidade de São Paulo 2015
Subjects:	Câncer de mama HER2 positivo Eventos adversos Farmacoepidemiologia Qualidade de vida Trastuzumabe Adverse events HER2 positive breast cancer Pharmacoepidemiology Quality of life Trastuzumab
Online Access:	http://www.teses.usp.br/teses/disponiveis/60/60137/tde-17042015-095050/

Similar Items

Uso de trastuzumabe para o tratamento de mulheres com câncer de mama HER2 positivo: um estudo farmacoepidemiológico
by: Ayres, Lorena Rocha
Published: (2015)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
by: L G Zhukova, et al.
Published: (2018-06-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
by: Zhou P, et al.
Published: (2016-04-01)

Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
by: Li X, et al.
Published: (2021-07-01)

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
by: Darryl P. Leong, MBBS, MPH, MBiostat, PhD, et al.
Published: (2019-09-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
by: Tomas Baldassarre, et al.
Published: (2017-10-01)

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
by: Iain R. Macpherson, et al.
Published: (2019-12-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01)

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer∗
by: Erica L. Mayer, MD, MPH
Published: (2020-06-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
by: Paul Stewart, et al.
Published: (2020-12-01)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
by: Guang-Yi Sun, et al.
Published: (2021-01-01)

Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
by: Fu XM, et al.
Published: (2018-09-01)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
by: Sagar Sardesai, et al.
Published: (2020-11-01)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
by: Lei L, et al.
Published: (2019-04-01)

A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
by: Haruta Rumi, et al.
Published: (2011-11-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Pertuzumab and trastuzumab: the rationale way to synergy
by: SANDRINE RICHARD, et al.
Published: (2016-01-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
by: Tiziana Triulzi, et al.
Published: (2019-01-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
by: Xin Li, et al.
Published: (2018-08-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
by: María del Mar Noblejas-López, et al.
Published: (2021-03-01)

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
by: Louise Hiller, et al.
Published: (2018-04-01)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
by: Alice Indini, et al.
Published: (2021-04-01)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
by: E. V. Lubennikova, et al.
Published: (2017-11-01)

Trastuzumab administration during pregnancy: un update
by: Angeliki Andrikopoulou, et al.
Published: (2021-04-01)

Trastuzumab: updated mechanisms of action and resistance in breast cancer
by: Francois X. Claret, et al.
Published: (2012-06-01)